Skip to main content
All Posts By

Jordan Bouclin

Press Release

Variational AI Adds Leading Oncology Researchers to Scientific Advisory Board

Leading Cancer and Drug Discovery Biologists Dr. John F. Boylan and Dr. Mads Daugaard Join SAB Vancouver, BC – June 27, 2022 – Variational AI, developer of generative AI-based drug discovery platform for novel kinase inhibitors, today announced that it has added industry and scientific leaders Dr. John F. Boylan and Dr. Mads Daugaard to the company’s Scientific Advisory Board. “We are pleased to welcome Drs Boylan and Daugaard to our scientific advisory board,” said Handol Kim, co-Founder and CEO, Variational AI. “Their respective expertise in cell biology and biology complements our existing strengths in machine learning and chemistry and will help us focus on rapidly developing novel multi-targeted kinase inhibitors for oncology. We look forward to working with our SAB members to bring new therapeutics to market to positively impact patient outcomes.” Dr. John F. Boylan is a cell biologist by training focused on oncology drug discovery with a record of clinical success, contributing to 12 development candidates, 8 drugs that reached first-in-human clinical trials, and one approved drug; Vemurafenib (mutant BRAF inhibitor).  His broad drug discovery success encompasses small molecule, antibody, and antibody drug conjugate modalities. Dr. Boylan has led multidisciplinary teams and departments seeking to discover novel…
Jordan Bouclin
June 27, 2022